nach oben

Erschienen in:

01.07.2008 | Review

Oxidative stress and the pathogenesis of scleroderma: the Murrell’s hypothesis revisited

verfasst von: Armando Gabrielli, Silvia Svegliati, Gianluca Moroncini, Giovanni Pomponio, Mariarosaria Santillo, Enrico V. Avvedimento

Erschienen in: Seminars in Immunopathology | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Systemic sclerosis (SSc, scleroderma) is a devastating, immune-mediated, multisystem disorder characterized by microvasculature damage, circulating autoantibodies, and fibroblast activation, leading to massive fibrosis of skin, vessels, muscles, and visceral organs. Scleroderma causes disability and death as the result of end-stage organ failure. At present, no specific diagnostic nor therapeutic tools are available to handle the disease. In spite of significant effort, the etiology and pathogenesis of SSc remain obscure and, consequently, the disease outcome is unpredictable. Several years ago, Murrell suggested a unifying hypothesis linking the pathogenesis of scleroderma to the generation of a large excess of reactive oxygen species. This hypothesis has been substantiated by several reports indicating the presence of an abnormal redox state in patients with scleroderma. This review will summarize the available evidence supporting the link between free radicals and the main pathological features of scleroderma.

Jimenez AS, Derk TC (2004) Following the molecular pathway toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 140:37–50PubMed

Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117:557–567PubMed

Murrell DF (1993) A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 28:78–85PubMed

Herrick AL, Rieley F, Schofield D et al (1994) Micronutrient antioxidant status in patients with primary Raynaud’s phenomenon and systemic sclerosis. J Rheumatol 21:1477–1483PubMed

Lundberg AC, Akesson A, Akesson B (1992) Dietary intake and nutritional status in patients with systemic sclerosis. Ann Rheum Dis 51:1143–1148PubMedCrossRef

Bruckdorfer KR, Hillary JB, Bunce T et al (1995) Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum 38:1060–1067PubMed

Iwata Y, Ogawa F, Komura K et al (2007) Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress. Rheumatology 46:790–795PubMed

Tikly M, Channa K, Theodorou P et al (2006) Lipid peroxidation and trace elements in systemic sclerosis. Clin Rheumatol 25:320–324PubMed

Stein CM, Tanner SB, Awad JA et al (1996) Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 39:1146–1150PubMed

10.

Cracowski JL, Marpeau C, Carpentier PH et al (2001) Enhanced in vivo lipid peroxidation in scleroderma spectrum disorders. Arthritis Rheum 44:1143–1148PubMed

11.

Cracowski JL, Carpentier PH, Imbert B et al (2002) Increased urinary F2-isoprostanes in systemic sclerosis, but not in primary Raynaud’s phenomenon: effect of cold exposure. Arthritis Rheum 4:1319–1323

12.

Volpe A, Biasi D, Caramaschi P et al (2006) Levels of F2-isoprostanes in systemic sclerosis: correlation with clinical features. Rheumatology 45:314–320PubMed

13.

Balbir-Gurman A, Braun-Moscovici Y, Livshitz V et al (2007) Antioxidant status after iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis. Clin Rheumatol 26:1517–1521PubMed

14.

Beckman JS, Beckman TW, Chen J et al (1990) Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Aca Sci U S A 87:1620–24

15.

Clancy RM, Amin AR, Abramson SB (1998) The role of nitric oxide in inflammation and immunity. Arthritis Rheum 41:1141–1151PubMed

16.

Matucci CM, Kahaleh MB (2002) Beauty and the beast. The nitric oxide paradox in systemic sclerosis. Rheumatology 41:843–847

17.

Yamamoto Y, Katayama I, Nishioka K (1998) Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. J Rheumatol 25:314–317PubMed

18.

Dooley A, Gao B, Bradley N et al (2006) Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology 45:676–684PubMed

19.

Takagi K, Kawaguchi Y, Hara M et al (2003) Serum nitric oxide (NO) levels in systemic sclerosis patients: correlation between NO levels and clinical features. Clin Exp Immunol 134:538–544PubMed

20.

Allanore Y, Borderie D, Hilliquin P et al (2001) Low levels of nitric oxide (NO) in systemic sclerosis: inducible NO synthase production is decreased in cultured peripheral blood monocyte/macrophage cells. Rheumatology 40:1089–1096PubMed

21.

Cotton A, Herrick AL, Jayson MI et al (1999) Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis. J Pathol 189:273–278PubMed

22.

Kharitonov SA, Cailes JB, Black CM et al (1997) Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax 52:1051–1055PubMedCrossRef

23.

Moodley YP, Lalloo UG (2001) Exhaled nitric oxide is elevated in patients with progressive systemic sclerosis without interstitial lung disease. Chest 119:1449–1454PubMed

24.

Malerba M, Radaeli A, Ragnoli B et al (2007) Exhaled nitric oxide levels in systemic sclerosis with and without pulmonary involvement. Chest 132:575–580PubMed

25.

Tiev KP, Cabane J, Aubourg F et al (2007) Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide. Eur Respir J 30:26–30PubMed

26.

Rolla G, Colagrande P, Scappaticci E et al (2000) Exhaled nitric oxide in systemic sclerosis: relationships with lung involvement and pulmonary hypertension. J Rheumatol 27:1693–1698PubMed

27.

Sambo P, Amico D, Giacomelli R et al (2001) Intravenous N-acetylcysteine for treatment of Raynaud’s phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol 28:2257–2262PubMed

28.

Herrick AL, Hollis S, Schofield D et al (2000) A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp Rheumatol 18:349–356PubMed

29.

Denton CP, Bunce TD, Dorado MB et al (1999) Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud’s phenomenon. Rheumatology 38:309–315PubMed

30.

Becker LB (2004) New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res 61:461–470PubMed

31.

Sambo P, Jannino L, Candela M et al (1999) Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. J Invest Dermatol 112:78–84PubMed

32.

Cracowski JL, Kom GD, Salvat-Melis M et al (2006) Postocclusive reactive hyperemia inversely correlates with urinary 15-F2t-isoprostane levels in systemic sclerosis. Free Radic Biol Med 40:1732–1737PubMed

33.

Sambo P, Svegliati Baroni S, Luchetti M et al (2001) Oxidative stress in scleroderma. Maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 44:2653–2664PubMed

34.

Svegliati Baroni S, Cancello R, Sambo P et al (2005) PDGF and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK 1/2. Amplification of ROS-ERK-Ras signalling in systemic sclerosis fibroblasts. J Biol Chem 280:36474–36482

35.

Allanore Y, Borderie D, Périanin A et al (2005) Nifedipine protects against overproduction of superoxide anion by monocytes from patients with systemic sclerosis. Arthritis Res Ther 7:R93–R100PubMed

36.

Failli P, Palmieri L, D’Alfonso C et al (2002) Effect of N-acetyl-l-cysteine on peroxynitrite and superoxide anion production pf lung alveolar macrophage in systemic sclerosis. Nitric Oxide 7:277–282PubMed

37.

Yamamoto T, Sawada Y, Katayama I et al (1998) Increased production of nitric oxide stimulated by interleukin-1beta in peripheral blood mononuclear cells in patients with systemic sclerosis. Br J Rheumatol 37:1123–1125PubMed

38.

Bedard K, Krause KE (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87:245–313PubMed

39.

Lassegue B, Sorescu D, Szocs K et al (2001) Novel gp91 (phox) homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signalling pathway. Circ Res 88:888–894PubMed

40.

Touyz RM, Chen X, Tabet F et al (2002) Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res 90:1205–1213PubMed

41.

Cucoranu I, Clempus R, Dikalova A et al (2005) NAD(P)H oxidase 4 mediates transforming growth factor-beta-1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 97:900–907PubMed

42.

Sturrock A, Cahill B, Norman K et al (2005) Transforming growth factor beta1 induces Nox4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 290:L661–L673PubMed

43.

Neufeld G, Cohen T, Gengrinovitch S et al (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9–22PubMed

44.

Thannickal VJ, Fanburg BL (1995) Activation of an H2O2-generating NADH in human lung fibroblasts by transforming growth factor-beta 1. J Biol Chem 270:30334–30338PubMed

45.

Chapple ILC (1997) Reactive oxygen species and antioxidants in inflammatory diseases. J Clin Periodontol 24:287–296PubMed

46.

Datla RS, Peshavariya H, Dusting GJ et al (2007) Important role of Nox4 type NADPH oxidase in angiogenic responses in human microvascular endothelial cells in vitro. Arterioscler Thromb Vasc Biol 27:2319–2324PubMed

47.

Ago T, Kitazono T, Ooboshi H et al (2004) Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation 109:227–233PubMed

48.

Ago T, Kitazono T, Kuroda J et al (2005) NAD(P)H oxidase in rat basilar arterial endothelial cells. Stroke 36:1040–1046PubMed

49.

Banfi B, Malgrange B, Knisz J et al (2004) Nox3: a superoxide-generating NADPH oxidase of the inner ear. J Biol Chem 279:46065–46072PubMed

50.

Furst R, Brueckl C, Kuebler WM et al (2005) Atrial natriuretic peptide induces mitogen-activated protein kinase phosphatase-1 in human endothelial cells via Rac1 and NAD(P)H oxidase/Nox2-activation. Circ Res 96:43–53PubMed

51.

Goyal P, Weissmann N, Grimminger F et al (2004) Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species. Free Radic Biol Med 36:1279–1288PubMed

52.

Higgings DF, Kimura K, Bernhardt WM et al (2007) Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 117:3810–3820

53.

Colston JT, de la Rosa SD, Strader JR et al (2005) H2O2 activates Nox4 through PLA2-dependent arachidonic acid production in adult cardiac fibroblasts. FEBS Lett 579:2533–2540PubMed

54.

Dhaunsi GS, Paintlia MK, Kaur J et al (2004) NADPH oxidase in human lung fibroblasts. J Biomed Sci 11:617–622PubMed

55.

Chamseddine AH, Miller JFJ (2003) gp91phox contributes to NADPH oxidase activity in aortic fibroblasts, but not smooth muscle cells. Am J Physiol Heart Circ Physiol 285:H2284–H2289PubMed

56.

Harris ML, Rosen A (2003) Autoimmunity in scleroderma: the origin, pathogenetic role and clinical significance of autoantibodies. Curr Opin Rheumatol 15:778–784PubMed

57.

Hasegawa M, Sato S, Fujimoto M et al (1998) Serum levels of interleukin 6 (IL-6) oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 25:308–313PubMed

58.

Hasegawa M, Fujimoto M, Kikuchi K et al (1997) Elevated serum levels of interleukin 4 (IL-4), IL-10 and IL-13 in patients with systemic sclerosis. J Rheumatol 24:328–332PubMed

59.

Valentini G, Baroni A, Esposito K et al (2001) Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation. J Clin Immunol 21:210–217PubMed

60.

Hesegawa M, Sato S, Ihn H et al (1999) Enhanced production of interleukin-6 (IL-6) oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology 38:612–617

61.

Mavalia C, Scaletti C, Romagnani P et al (1997) Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 151:1751–1758PubMed

62.

Li-Weber M, Giaisi M, Treiber MK et al (2002) Vitamin E inhibits IL-4 gene expression in peripheral blood T cells. Eur J Immunol 32:2401–2408PubMed

63.

King MR, Ismail AS, Davis LS et al (2006) Oxidative stress promotes polarization of human T cell differentiation toward a T helper 2 phenotype. J Immunol 176:2765–2772PubMed

64.

Ishikawa H, Carrasco D, Claudio E et al (1997) Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-kappaB2. J Exp Med 186:999–1014PubMed

65.

Casciola-Rosen L, Wigley F, Rosen A (1997) Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implication for pathogenesis. J Exp Med 185:71–79PubMed

66.

Obata F, Hoshino A, Toyama A (2006) Hydrogen peroxide increases interleukin-12 p40/p70 molecular ratio and induces Th2 predominant responses in mice. Scand J Immunol 63:125–130PubMed

67.

Peterson JD, Herzenberg LA, Vasquez K et al (1998) Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc Natl Acad Sci U S A 95:3071–3076PubMed

68.

Jeannin P, Delneste Y, Lecoanet-Henchoz S et al (1995) Thiols decrease human interleukin (IL) 4 production and IL-4-induced immunoglobulin synthesis. J Exp Med 182:1785–1792PubMed

69.

Prescott RJ, Freemont AJ, Jones CJ et al (1992) Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166:255–263PubMed

70.

Fleischmajer R, Perlish JS, Shaw KV et al (1976) Skin capillary changes in early systemic scleroderma. Electron microscopy and “in vitro” autoradiography with tritiated thymidine. Arch Dermatol 112:1553–1557PubMed

71.

Fleischmajer R, Perlish JS (1980) Capillary alterations in scleroderma. J Am Acad Dermatol 2:161–170PubMed

72.

Mitchell RN, Libby P (2007) Vascular remodelling in transplant vasculopathy. Circ Res 100:967–978PubMed

73.

Kuwana M, Okazaki Y, Yasuoka H et al (2004) Defective vasculogenesis in systemic sclerosis. Lancet 364:603–610PubMed

74.

Sgonc R, Gruschwitz MS, Dietrich H et al (1996) Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98:785–792PubMed

75.

Herron GS, Luz I, Romero LI (1998) Vascular abnormalities in scleroderma. Semin Cutan Med Surg 17:12–17PubMed

76.

Griendling KK, Sorescu D, Ushio-Fukai M (2000) NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86:494–501PubMed

77.

Lassègue B, Sorescu D, Szöcs K et al (2001) Novel gp91 (phox) homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res 88:888–894PubMed

78.

Marumo T, Schini-Kerth VB, Fissilthaler B et al (1997) Platelet-derived growth factor-stimulated superoxide anion production modulates activation of transcription factor NF-kappaB and expression of monocyte chemoattractant protein 1 in human aortic smooth muscle cells. Circulation 96:2361–2367PubMed

79.

Wang Z, Castresana MR, Newman WH (2004) Reactive oxygen species-sensitive p38 MAPK controls thrombin-induced migration of vascular smooth muscle cells. J Mol Cell Cardiol 36:49–56PubMed

80.

Zhang H, Schmeisser A, Garlichs CD et al (1999) Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc Res 44:215–222PubMed

81.

Pedruzzi E, Guichard C, Ollivier V (2004) NAD(P)H oxidase Nox-4 mediates 7-ketocholesterol-induced endoplasmic reticulum stress and apoptosis in human aortic smooth muscle cells. Mol Cell Biol 24:10703–10717PubMed

82.

Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK (1996) p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 271:23317–23321PubMed

83.

Rey FE, Pagano PJ (2002) The reactive adventitia: fibroblasts oxidase in vascular function. Thromb Vasc Biol 22:1962–1971

84.

Kawaguchi Y, Takagi K, Hara M et al (2004) Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum 50:216–226PubMed

85.

Holland JA, Meyer JW, Chang MM et al (1998) Thrombin stimulated reactive oxygen species production in cultured endothelial cells. Endothelium 6:113–121PubMed

86.

Bogatkevich GS, Gustio E, Oates JC et al (2004) Distinct PKC isoforms mediate cell survival and DNA synthesis in thrombin-induced myofibroblasts. Am J Physiol Lung Cell Mol Physiol 288:L190–L201PubMed

87.

Klareskog L, Gustaffson R, Scheynius A et al (1990) Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum 33:1534–1541PubMed

88.

Xue-yi Z, Jan-zhong Z, Ping T et al (1998) Expression of platelet-derived growth factor B chain and platelet-derived growth factor b-receptor in fibroblasts of scleroderma. J Dermatol Sci 18:90–97

89.

Abraham DJ, Varga J (2005) Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 26:587–595PubMed

90.

Murrell GAC, Francis MJO, Bromley L (1990) Modulation of fibroblast proliferation by oxygen free radicals. Biochem J 265:659–665PubMed

91.

Falanga V, Martin TA, Takagi H et al (1993) Low oxygen tension increases mRNA levels of alpha 1(I) procollagen in human dermal fibroblasts. J Cell Physiol 157:408–412PubMed

92.

Parola M, Pinzani M, Casini A et al (1993) Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen a(I) gene expression in human liver fat-storing cells. Biochem Biophys Res Commun 194:1044–1050PubMed

93.

Kinnula VL, Fattman CL, Tan RJ et al (2005) Oxidative stress in pulmonary fibrosis. A possible role for redox modulatory therapy. Am J Respir Crit Care Med 172:417–422PubMed

94.

Shi Y, Massagué J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113:685–700PubMed

95.

Trojanowska M (2002) Molecular aspects of scleroderma. Front Biosci 7:608–618

96.

Bellocq A, Azoulay E, Marullo S et al (1999) Reactive oxygen species and nitrogen intermediates increase transforming growth factor-beta 1 release from human epithelial alveolar cells through two different mechanisms. Am J Respir Cell Mol Biol 21:128–136PubMed

97.

Barcellos-Hoff MH, Dix TA (1996) Redox-mediated activation of latent transforming growth factor beta. Mol Endocrinol 10:1077–1083PubMed

98.

Hancock JT, Desikan R, Neill SJ (2001) Role of reactive oxygen species in cell signalling pathways. Biochem Soc Trans 29:345–350PubMed

99.

Sementchenko VI, Watson DK (2000) Ets target genes: past, present and future. Oncogene 19(55):6533–6548PubMed

100.

Arsalane K, Dubois CM, Muanza T et al (1997) Transforming growth factor-beta 1 is a potent inhibitor of glutathione synthesis in the lung epithelial cell line A 549: transcription effect on the GSH rate-limiting enzyme gamma-glutamylcysteine synthetase. Am J Respir Cell Mol Biol 17:599–607PubMed

101.

Factor VM, Kiss A, Woitach JT et al (1998) Disruption of redox homeostasis in the transforming growth factor-alpha/c-myc transgenic mouse model of accelerated hepatocarcinogenesis. J Biol Chem 273:15846–15853PubMed

102.

Ask K, Martin GE, Kolb M et al (2006) Targeting genes for treatment in idiopathic pulmonary fibrosis: challenges and opportunities, promises and pitfalls. Proc Am Thorac Soc 3:389–393PubMed

103.

Hoyle GW, Li J, Finkelstein JB et al (1999) Emphysematous lesions, inflammation, and fibrosis in the lungs of transgenic mice overexpressing platelet-derived growth factor. Am J Pathol 154:1763–1775PubMed

104.

Bae SY, sung JY Kim OS et al (2000) Platelet-derived growth factor-induced H2O2 production requires the activation of phosphatidylinositol 3-kases. J Biol Chem 275:10527–10531PubMed

105.

Park J, Ha H, Ahn HJ et al (2005) Sirolimus inhibits platelet-derived growth factor-induced collagen synthesis. Transplant Proc 37:3459–3462PubMed

106.

Rajkumar VS, Howelll K, Csiszar K et al (2005) Shared expression of phenotypic markers in systemic sclerosis indicates convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther 7:R1113–R1123PubMed

107.

Distler JH, Jungel A, Huber LC et al (2007) Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 56:311–322PubMed

108.

Svegliati Baroni SS, Santillo MR, Bevilacqua F et al (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis (scleroderma). N Engl J Med 354:2667–2676

Titel: Oxidative stress and the pathogenesis of scleroderma: the Murrell’s hypothesis revisited
verfasst von: Armando Gabrielli
Silvia Svegliati
Gianluca Moroncini
Giovanni Pomponio
Mariarosaria Santillo
Enrico V. Avvedimento
Publikationsdatum: 01.07.2008
Verlag: Springer-Verlag
Erschienen in: Seminars in Immunopathology / Ausgabe 3/2008
Print ISSN: 1863-2297
Elektronische ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-008-0125-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2008

NOX enzymes as novel targets for drug development

NOX enzymes and Toll-like receptor signaling

Priming of the neutrophil NADPH oxidase activation: role of p47phox phosphorylation and NOX2 mobilization to the plasma membrane

NOX enzymes and diabetic complications

Genetics and immunopathology of chronic granulomatous disease